Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Chemotherapy, Immunotherapy, and Probiotics in Resectable NSCLC
NCT04699721Phase 2Active, not recruiting
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Sep 2020
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies, Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bifidobacterium longum/lactobacillus acidophilus/enterococcus faecalis in non-small cell lung cancer (NSCLC), sponsored by Xiangya Hospital, Central South University. Primary endpoint: Pathological complete response. Started Sep 2020; status: active, not recruiting.
02
Drugs
bifidobacterium longum/lactobacillus acidophilus/enterococcus faecalis
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04699721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04699721.